Background: Neuroblastoma (NB) is the most common solid tumor found in children, and deletions within the 11q region are observed in 11% to 48% of these tumors. Notably, such tumors are associated with poor prognosis; however, little is known regarding the molecular targets located in 11q. Methods: Genomic alterations of ATM, DNA damage response (DDR)-associated genes located in 11q (MRE11A, H2AFX, and CHEK1), and BRCA1, BARD1, CHEK2, MDM2, and TP53 were investigated in 45 NB-derived cell lines and 237 fresh tumor samples. PARP (poly [ADP-ribose] polymerase) inhibitor sensitivity of NB was investigated in in vitro and in vivo xenograft models. All statistical tests were two-sided. Results: Among 237 fresh tumor samples, ATM, MRE11A, H2AFX, and/or CHEK1 loss or imbalance in 11q was detected in 20.7% of NBs, 89.8% of which were stage III or IV. An additional 7.2% contained ATM rare single nucleotide variants (SNVs). Rare SNVs in DDR-associated genes other than ATM were detected in 26.4% and were mutually exclusive. Overall, samples with SNVs and/or copy number alterations in these genes accounted for 48.4%. ATM-defective cells are known to exhibit dysfunctions in homologous recombination repair, suggesting a potential for synthetic lethality by PARP inhibition. Indeed, 83.3% NB-derived cell lines exhibited sensitivity to PARP inhibition. In addition, NB growth was markedly attenuated in the xenograft group receiving PARP inhibitors (sham-treated vs olaprib-treated group; mean [SD] 
Advanced neuroblastoma (NB) is one of the most intractable childhood cancers (1) . MYCN amplification is a wellcharacterized genetic alteration in NB that directly associates with advanced disease and poor prognosis. In addition to MYCN amplification, several other genome alterations are associated with NB. Mosse et al. and our group reported that activating mutations in the tyrosine kinase domain of the ALK oncogene account for 2% of familial NB and 5% to 10% of sporadic NB cases (2, 3) . Genome-wide association studies have identified single nucleotide variants (SNVs) within the putative gene FLJ22536 in chromosome band 6p22.3, BARD1 in 2q35, and LMO1 in 11p15. 4 that are associated with development of NB (4) (5) (6) . In addition to gene mutations, genome copy alterations are also implicated in NB; for example, an unbalanced gain of 17q is observed in approximately half of NBs. Loss of 1p, 3p, and 11q is also observed in the advanced stage of NB and is associated with an unfavorable prognosis (7) (8) (9) . Deletion of 11q is observed in 11% to 48% of NB cases; these cases, which fall into distinct genetic subtypes, exhibit no MYCN amplification (10, 11) . However, little is known about the molecular target(s) located in 11q. CADM1 was identified as a candidate gene in 11q23 in NB (12, 13) . The 11q21-24 is unique in cancer genetics because it contains many cancerassociated genes in addition to CADM1, including MRE11A, ATM, KMT2A, H2AFX, CBL, CHEK1, ETS1, FLI1, and TP53AIP1.
DNA damage response (DDR) is crucial for maintenance of genome integrity. ATM is a master regulator of DDR, and various other molecules involved in the DDR are regulated via ATM. For example, CHEK1 is a signaling molecule that activates the G2/M cell cycle checkpoint, and H2AFX is a histone that functions specifically during DNA damage. In addition, ATM plays a critical role in DNA repair in both the nonhomologous end-joining (NHEJ) and homologous recombination repair (HRR) pathways (14) (15) (16) (17) . Cells constantly undergo DNA damage caused by agents such as oxygen-free radicals and natural ionizing radiation. Therefore, cellular DNA in mammalian cells is under constant DNA-damaging stress, posing the risk of mutation. DNA damage is sensed by ATM and ATR, which upon activation initiate DDR pathways and trigger cell cycle checkpoints, apoptosis, or the DNA repair machinery (18) . Thus, the DDR is the most important factor in maintaining genome integrity. However, once DNA damage occurs in genes that play a crucial role in the DDR itself, the checkpoint pathway is compromised; as a result, cells acquire a growth advantage and can undergo transformation more readily. Such cells, which are genomically unstable, start to proliferate and accumulate additional complex mutations, contributing to the stepwise evolution of tumorigenesis (19) (20) (21) (22) . MYC activation activates the ATM-dependent DDR pathway and CDKN2A-dependent pathway (23, 24) . In addition, ATM exerts a tumor suppressor function through MYC (25) . Thus, ATM and MYC act in the same circuit in the context of tumorigenesis and tumor suppression.
In this study, we investigated the role of ATM and DDRassociated molecules located in 11q, MRE11A, H2AFX, and CHEK1, as well as BRCA1, BARD1, CHEK2, MDM2, and TP5.
Methods

Samples and Cell Lines
The SJNB series and the UTP-N-1 cell lines were gifts from A. 19-9 and 444) . To confirm the somatic/germline origins of the detected mutations, corresponding normal specimens (mononuclear cells from peripheral blood or bone marrow with no tumor cells) from nine subjects with NB were also analyzed. To evaluate SNVs of ATM in a healthy Japanese cohort, mononuclear cells from the peripheral blood of 171 healthy volunteers were also used.
DNA Sequencing
DNA sequencing was performed by target sequencing using the HiSeq 2000 or MiSeq platform (Illumina, San Diego, CA). Primers were designed to cover the entire coding exons of ATM and other DDR-associated genes (Supplementary Table 2 , available online).
Animal Studies and Tumor Xenografts
All animal care procedures were carried out in accordance with institutional guidelines approved by Tokyo Medical and Dental University (Tokyo, Japan). All mice were kept in a pathogen-free unit in the vivarium of Tokyo Medical and Dental University. Eight-week-old female NSG mice (Charles River, Yokohama, Japan) were anesthetized, and 1 Â 10 7 SK-N-DZ or SK-N-SH cells were injected subcutaneously into the back skin for xenografts. Oral administration of the PARP inhibitor (50 mg/kg body weight) was initiated on day 2 and continued every other day, three times a week, for a total of three weeks. The same volume of the carrier used to dissolve the PARP inhibitor was administered orally in controls. Tumor volume was measured every two to three days.
Data Analysis
Evaluation of SNVs was performed using public source databases. Polymorphism and allele frequency of SNVs were determined using dbSNP build 131/132, 1000 Genomes Project, and the Human Genetic Variation database (HGVD).
The Methods for Survival Curves
Survival curves were constructed according to the methods of Kaplan and Meier. The time to an event for the overall survival analysis was calculated as the time from first diagnosis until the time of death or the time of last contact if the patient was alive.
Statistical Analysis
P values were calculated by Mann-Whitney U test for DR-GFP assay. Tumor volumes from the mouse experiments were analyzed using the Student's t test. Comparisons of the survival curves were performed with a log-rank test. All statistical tests were two-sided, and a P value of less than .05 was considered statistically significant. Detailed information regarding the other methods is available in the Supplementary Materials and Methods (available online).
Results
Copy Number Alteration of ATM and Other DDRAssociated Genes in NB Approximately 14% to 48% of NB cases are associated with loss or imbalance of 11q, the site of the ATM locus (10, 11, 26) . Accordingly, we investigated genomic copy number alteration of the ATM gene in NB-derived cell lines. Of the 45 cell lines examined, 12 exhibited ATM deletion and four exhibited uniparental disomy (UPD; total 35.6%) (Supplementary Table 3 Comprehensive copy number analysis in 39 cell lines revealed that the DDR-associated molecules H2AFX, CHEK1, and MRE11A were deleted with almost the same frequency as ATM (Table 1 ; Supplementary Figure 1 , available online).
These observations in cell lines prompted us to investigate further using clinical samples. Initially, 78 fresh NB samples were screened as a discovery cohort. Loss of the ATM locus was observed in 14.1% (11/78) of tumor samples. Furthermore, 22.2% (10/45) of stage III and IV cases had lost ATM, indicating that 90.9% (10/11) of ATM-deleted cases were stage III or IV (Table 1) . To further confirm these observations, we performed comprehensive copy number analysis using an additional 159 fresh NB tumor samples as a validation cohort. Loss or UPD of 11q, including deletion or UPD of ATM, H2AFX, CHEK1, and MRE11A, was observed in 23.9% of these samples (38/159), and 89.5% (34/38) of 11q imbalanced cases were stage III or IV (Table 1 and Figure 1A ). In total ATM, MRE11A, H2AFX, and/or CHEK1 loss or imbalance in 11q was detected in 20.7% (49/237) of NBs, 89.8% (44/49) of which were stage III or IV. Statistically significant copy number gains or losses were evaluated by GISTIC algorithms using 133 fresh NB samples (27) . Locus amplification of MYCN (2p25.1-2p21), MDM2 (12q15), and 17q12-17q25 exhibited low q values. Among the loci exhibiting low q values, regions 11q22.1 to 11q24.3 contained the DDR-associated genes MRE11A, ATM, H2AFX, and CHEK1 ( Figure 1 , B and C).
ATM Gene Alteration in NB
Subsequently, ATM gene mutations were investigated using 45 NB-derived cell lines. Sequencing analysis identified five ATM SNVs (Table 1; Supplementary Table 3 , available online). V2716A, identified in the IMR-32 line, is located in the ATPbinding site within the catalytic domain of ATM and was previously characterized as a pathogenic dominant-negative mutation in a family exhibiting mild ataxia telangiectasia (28, 29) . IMR-32 also harbored UPD of the ATM locus, rendering the cells homozygous for ATM mutation. Notably, GOTO cells harbored deletion of 11q, including the ATM region along with a nonsense mutation in the ATM gene, rendering the cells ATM-null.
To further confirm these observations, we analyzed clinical fresh NB tumor samples. Seven ATM nonsynonymous SNVs in six subjects and two intragenic deletions were identified in the 78 fresh NB samples comprising the discovery cohort (7.6% and 2.6% of subjects, respectively; total ¼ 10.2%) ( Table 1;  Supplementary Table 4 , available online). Except in one case, all nucleotide changes were identified as germline variants. In addition, nonsynonymous ATM SNVs were identified in 5.7% (9/ 159) of samples in the validation cohort (Table 1; Supplementary  Table 4 , available online). The status of germline variants was not investigated in all cases, but two cases were confirmed as germline SNVs, and data from allele frequency estimation suggested that seven of nine SNVs were germline mutations. Overall, nonsynonymous ATM SNVs were identified in 7.2% (17/ 237) of fresh NB samples, and 58.8% (10/17) of the cases in which nonsynonymous ATM SNVs were identified were stage III and IV NB. ATM SNVs were dispersed throughout the entire ATM region (Supplementary Figure 2A , available online). Among them, V2716A and K2749I mutations were both identified in the region encoding the ATM catalytic domain. Notably, in fresh tumor samples, ATM SNVs and 11q loss were mutually exclusive (Figure 2A ).
DDR-Associated Gene Alteration in Fresh NB Samples
Target sequencing using 39 NB-derived cell lines and a COSMIC database search identified six nonsynonymous SNVs of Table 6 , available online). Intriguingly, SNVs in DDR-associated genes, including ATM, were mutually exclusive (Figure 2A ). At least one SNV was identified in 26.4% (33/159) of fresh NB samples ( Figure 2B ). Overall, samples with SNVs and/or copy number alterations in these genes accounted for 48.4% (77/159) of all NB cases.
Survival of NB With DDR-Associated Gene Alterations
We compared survival of all stage cases ( Figure 3 ) and cases in stages III and IV (Supplementary Figure 3 , available online) and found that among these patients there was no difference in prognosis between those with and without DDR-associated gene alterations (P ¼ .08 and P ¼ .41, respectably).
Functional Analysis of Identified SNVs
Because ATM harbors various single nucleotide polymorphisms (SNPs) in approximately 5% of the population, we sequenced ATM and BARD1 in control DNA from 171 healthy individuals to evaluate the consequence of SNVs identified in tumor samples. SNVs in ATM and BARD1 were detected in 5.3% (9/171) and 1.2% (2/171), respectively (Supplementary Table 7 , available online). To determine whether the rare SNVs identified in the discovery, validation, and healthy cohorts were functionally altered or represent neutral polymorphisms, we performed in vitro functional assays. ATM-defective cells exhibit radiation hypersensitivity; thus SNVs were subcloned into expression vectors and transduced into ATM-null fibroblasts to assess their functional effect on radiosensitivity. All SNVs identified in the NB cohort, except V1841I, failed to restore (or only partially restored) the hyperradiosensitivity phenotype of ATM-null cells, suggesting that these SNVs, except for V1841I, are functionally defective ( Figure  4A ). Although V1841I was identified as a somatic mutation and was expected to be functionally defective, V1841I is more likely to be a passenger mutation. Furthermore, two SNVs, S1455R and K2749I, were observed in both healthy control and tumor samples. Functional evaluation of these two SNVs revealed that complementation with either SNV moderately reversed radiosensitivity ( Figure 4B) . By contrast, all other SNVs originating from healthy control individual samples fully restored radiosensitivity, reflecting normal ATM function ( Figure 4C ). vs stage III and IV), suggesting loss, mutation, or inactivation of ATM in the latter samples ( Figure 5, A and B) .
DDR Activation in Fresh NB Samples
Characterization of NB-Derived Cell Lines
Consistent with the results of genomic analysis, immunoblotting revealed that cell lines exhibiting haploid loss of the ATM gene locus exhibited reduced ATM protein expression ( Figure  6A ). To clarify the relationship between ATM gene alteration and ATM function in NB-derived cell lines, we investigated ATM-dependent DDR. ATM activity was evaluated in irradiated cells by measuring phosphorylation of the downstream substrate SMC1 because ATM levels varied between cell lines, whereas SMC1 expression was uniform. As anticipated, SMC1 phosphorylation was attenuated in clones with ATM haploinsufficiency, as well as in ATM-null GOTO cells. Notably, in the three clones that contained an intact ATM locus, CHP-134, IMR-32, and NB-9, SMC1 phosphorylation was also impaired. Among them, IMR-32 carried a homozygous V2716A ATM mutation due to UPD. By contrast, the ATM-competent lines SK-N-BE, SK-N-SH, and NB-69 exhibited normal responses ( Figure 6B ). Although the reason underlying the defective SMC1 phosphorylation in CHP-134 and NB-9 remains elusive, the majority of the NBderived cell lines were functionally defective in the DDR regulated by ATM.
Sensitivity of NB Cells to PARP Inhibitors
PARP inhibitors (PARPi) induce synthetic lethality in HRRdefective cells (30, 31) . ATM is involved in HRR, and PARPi is therapeutically effective in ATM-deleted mantle cell lymphoma (32) . MRE11, H2FX, and BARD1 also affect the HRR process, either directly or via ATM. Accordingly, we investigated the sensitivity of NB-derived cell lines to the PARP inhibitor olaparib. Except for SK-N-SH and SK-N-BE, which retain wild-type ATM and normal DDR ( Figure 6B ), 83.3% (10/12) of NB-derived cell lines exhibited elevated olaparib sensitivity ( Figure 7A ). Next, HRR activity was measured using DR-GFP assay. Confirming the previously published data (33), ATM inhibitor KU55933 treatment reduced GFP-positive cell number after I-SceI transduction, suggesting attenuated HRR efficiency of ATM-competent SK-N-BE cells (P ¼ .004) ( Figure 7B ). In addition, most ATM mutants identified from fresh tumor samples, except for L1956H and R2691C, could not rescue PARPi sensitivity of ATM-null shown as either white (not detectable) or black (detectable) bars. P values were calculated using a two-sided Mann-Whitney U test. HE ¼ hematoxylin and eosin staining.
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Discussion
Ataxia telangiectasia and Nijmegen breakage syndrome are associated with a variety of tumors, including leukemias and lymphomas; however, NB has rarely been associated with chromosomal breakage syndromes (34, 35) , although several reports have described development of NB in Fanconi anemia (36) (37) (38) (39) (40) . In the present study, we detected loss or imbalance of the ATM locus of fresh NB subjects. Mandriota et al. also reported that ATM deletions are present in 14 of 50 (28%) patients with NB and that progression of NB is promoted by silencing of ATM (41) . Loss of ATM was linked with poor prognoses in mantle cell lymphoma and chronic lymphocytic leukemia (26, 42) . Therefore, prognostic significance based on ATM loss may be universally valuable across various tumors, including NB. This study revealed that 7.2% of NB samples carry ATM SNVs. Some ATM SNVs are present at the germline level (Supplementary Table 2 , available online). However, in this cohort, family history, such as that pertaining to cancer segregation or ataxia, was not obtained. Because most A-T-associated mutations are nonsense mutations, we anticipated that these patients would not present with classical A-T. Previously, biallelic missense mutation in the ATM gene was identified as responsible for adult-onset dystonia (43) . Because NB develops at a relatively young age and is difficult to cure at advanced stages, it is possible that ATM germline SNVs also confer the potential risk of dystonia development later in life. ATM germline missense mutations contribute to cancer susceptibility (44) (45) (46) . For example, rare ATM SNVs confer strong cancer predisposition in familial pancreatic cancer; however, familial pancreatic cancer with ATM SNVs is relatively rare (47, 48) . Previous wholeexome sequencing of 240 NB samples identified rare, potentially pathogenic, germline variants in ALK, CHEK2, PINK1, and BARD1 (49); another study identified three ATM SNVs (4). Together with the results of the present study, these findings suggest that pathogenic germline variants of ATM and/or other DDRassociated molecules, including BARD1, are genetic risk factors for NB susceptibility.
Although most instances of 11q deletion do not overlap with MYCN amplification in NB, a relationship between MYC and ATM has been reported. Activation of MYC augments ATMdependent DDR (50) , and DMAP1, located at chromosome 1p, promotes MYCN-dependent ATM activation (51) . In turn, the DDR plays a critical role in malignant transformation: specifically, ATM suppresses tumorigenesis in response to MYC (23, 25) . These data indicate that ATM functions as a tumor suppressor following MYCN amplification. Notably, MYCN overexpression induces expression of miR-421, which downregulates ATM expression in NB cells (52) . These observations suggest that most cases of advanced NB exhibit downregulation of ATM, either directly because of 11q deletion or mediated by miR-421 in MYCN-amplified NB. Thus, we speculate that the ATMdependent DDR response is suppressed to various extents in most cases of advanced NB. In addition, defects in other molecules associated with DDR, such as FANCM, FAN1, PALB2, MRE11A, and BARD1, were previously reported (49, 53) and observed in the present study. Furthermore, most NB-derived cell lines exhibited increased sensitivity to PARPi. In the present study, CHP-134 and NB-9 exhibited attenuated phosphorylation of SMC1 after DNA damage and elevated PARPi sensitivity without ATM loss or mutation. It is likely that additional molecules involved in DDR, which were not identified in this study, may contribute to PARPi sensitivity. Indeed, BRCA1, BRCA2, and BARD1 SNVs were detected in SK-N-DZ, CHP-134, and NB-69 (Supplementary Table 4 , available online).
Our study is not without limitations. It remains unclear how and when the mutation of DDR-associated molecules, or loss of 11q, occurs during tumor development and progression. In this study, we could not compare the frequency of mutations in DDR-associated molecules or 11q loss between initial samples and relapsed or metastatic region. Maesechia et al. reported that 11q deletion was present from the early stage of tumor in stage IV NB, while 11q deletion occurred prior to 3p loss. This observation highlights the critical role of 11q deletion in stage IV tumors and suggests that structural 11q aberration confers tumor aggressiveness as a consequence of chromosome instability (54) .
Multiple DDR-associated genes located at the 11q locus were deleted simultaneously. However, in our study, we could not examine how the combination of haploinsufficiency associates with tumor development. Actually, Atm, Mre11a, Chek1, or H2afx heterozygous knockout mice did not exhibit increased tumor growth following olaparib treatment. F) As in (E), except that SK-N-SH was transplanted. Four mice were used in each treatment group. Error bars represent standard deviation. P value was calculated using a two-sided Mann-Whitney U test. susceptibility. It is curious to examine Atm, Mre11a, Chek1, and H2afx quad heterozygous knockout mice.
Several reports have described PARP inhibition in NB but did not extensively investigate DDR. Norris et al. reported that olaparib inhibits the growth of pediatric solid tumor cell lines, including those derived from NB. The addition of olaparib to DNAdamaging agents results in additive or synergistic interactions (55) . Muller et al. proposed that a combination of the PARP inhibitor MK-4827 and radiation may be an effective therapy for children with high-risk NB (56) . Preclinical data suggest that PARPi may potentiate the effects of radiotherapy not only in NB, but also in several other tumor types (57) . Combination chemotherapy using PARPi with alkylating agents, platinum agents, or radiotherapy may effectively suppress NB progression. Therefore, we believe that the use of PARPi represents a promising therapeutic approach for specifically targeting HRR-defective NB. 
